Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists track cancer Drug's Long-Term risks in major safety study

NCT ID NCT02141438

Completed Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

Summary

This study followed over 1,400 men with advanced prostate cancer that had spread to their bones to monitor the long-term safety of the treatment Radium-223. Researchers tracked serious side effects, bone marrow health, and the risk of developing a second, unrelated cancer for up to seven years after treatment. The goal was to better understand the real-world risks and benefits of this therapy.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Study site

    Anchorage, Alaska, United States

  • Study site

    Scottsdale, Arizona, United States

  • Study site

    Daly City, California, United States

  • Study site

    Long Beach, California, United States

  • Study site

    Sacramento, California, United States

  • Study site

    San Diego, California, United States

  • Study site

    Colorado Springs, Colorado, United States

  • Study site

    Boca Raton, Florida, United States

  • Study site

    Fort Myers, Florida, United States

  • Study site

    Jacksonville, Florida, United States

  • Study site

    Lakewood Rch, Florida, United States

  • Study site

    Plantation, Florida, United States

  • Study site

    Atlanta, Georgia, United States

  • Study site

    Decatur, Georgia, United States

  • Study site

    Honolulu, Hawaii, United States

  • Study site

    Evanston, Illinois, United States

  • Study site

    Warrenville, Illinois, United States

  • Study site

    Wichita, Kansas, United States

  • Study site

    Ashland, Kentucky, United States

  • Study site

    New Orleans, Louisiana, United States

  • Study site

    Baltimore, Maryland, United States

  • Study site

    Rockville, Maryland, United States

  • Study site

    Towson, Maryland, United States

  • Study site

    Boston, Massachusetts, United States

  • Study site

    Troy, Michigan, United States

  • Study site

    St Louis, Missouri, United States

  • Study site

    Billings, Montana, United States

  • Study site

    Omaha, Nebraska, United States

  • Study site

    Lebanon, New Hampshire, United States

  • Study site

    Neptune City, New Jersey, United States

  • Study site

    Township, New Jersey, United States

  • Study site

    Buffalo, New York, United States

  • Study site

    East Setauket, New York, United States

  • Study site

    Lake Success, New York, United States

  • Study site

    Winston-Salem, North Carolina, United States

  • Study site

    Middleburg Heights, Ohio, United States

  • Study site

    Oklahoma City, Oklahoma, United States

  • Study site

    Springfield, Oregon, United States

  • Study site

    Abington, Pennsylvania, United States

  • Study site

    Charleston, South Carolina, United States

  • Study site

    Myrtle Beach, South Carolina, United States

  • Study site

    Nashville, Tennessee, United States

  • Study site

    Houston, Texas, United States

  • Study site

    Lubbock, Texas, United States

  • Study site

    San Antonio, Texas, United States

  • Study site

    Temple, Texas, United States

  • Study site

    Charlottesville, Virginia, United States

  • Study site

    Virginia Beach, Virginia, United States

  • Study site

    Seattle, Washington, United States

  • Study site

    Multiple Locations, Argentina

  • Study site

    Multiple Locations, Austria

  • Study site

    Multiple Locations, Belgium

  • Study site

    Multiple Locations, Canada

  • Study site

    Multiple Locations, Colombia

  • Study site

    Multiple Locations, Czechia

  • Study site

    Multiple Locations, Denmark

  • Study site

    Multiple Locations, France

  • Study site

    Multiple Locations, Germany

  • Study site

    Multiple Locations, Greece

  • Study site

    Multiple Locations, Israel

  • Study site

    Multiple Locations, Italy

  • Study site

    Multiple Locations, Luxembourg

  • Study site

    Multiple Locations, Mexico

  • Study site

    Multiple Locations, Netherlands

  • Study site

    Multiple Locations, Portugal

  • Study site

    Multiple Locations, Spain

  • Study site

    Multiple Locations, Sweden

  • Study site

    Multiple Locations, United Kingdom

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER